BiotechTube
Glycostem

Glycostem

Oss, Netherlands· Est.
glycostem.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20.5M

Overview

Glycostem Therapeutics is a pioneering developer of allogeneic, off-the-shelf NK cell immunotherapies derived from umbilical cord blood stem cells. Its core technology platform enables the production of highly pure, safe, and cost-effective NK cell products, with a lead candidate, oNKord®, in a pivotal Phase I/IIa trial for AML. The company has established a strategic partnership with medac GmbH for commercialization and is expanding its pipeline to include next-generation CAR-NK and other engineered NK cell therapies targeting both hematological and solid tumors.

Oncology

Technology Platform

Proprietary platform for expanding and differentiating highly pure, functional Natural Killer (NK) cells from umbilical cord blood-derived CD34+ stem cells, without the use of feeder cells. Supports development of both unmodified and engineered (e.g., CAR) off-the-shelf, allogeneic NK cell therapies.

Funding History

3
Total raised:$20.5M
Series B$12M
Series A$6.5M
Grant$2M

Opportunities

The growing demand for safer, off-the-shelf cellular immunotherapies presents a major opportunity, particularly in AML where unmet need is high.
Successful validation of its platform with oNKord® could enable rapid expansion into other hematological cancers and solid tumors through engineered NK cell programs.

Risk Factors

Clinical failure of the lead candidate oNKord® in ongoing trials is the primary risk.
The company also faces intense competition in the NK cell therapy space, technological hurdles in developing effective engineered NK cells, and the financial risks associated with being a pre-revenue, clinical-stage biotech.

Competitive Landscape

Glycostem competes in a rapidly evolving field with numerous players developing allogeneic NK and CAR-NK therapies, including Fate Therapeutics, Nkarta, Affimed, and large pharma partners. Differentiation hinges on its feeder-cell-free manufacturing process, safety profile, and cost-effectiveness.

More companies in Cell & Gene Therapy →More companies in Netherlands →